HIV screening strategies in blood donors:a cost-effectiveness analysis
Objective To analyze the cost and effectiveness of different HIV screening strategies based on multi-center HIV residual risk study,so as to provide reference for blood centers to adopt appropriate HIV testing strategies.Methods According to the HIV screening and confirmation of blood donors in three blood centers in Anhui Province,the residual risk of different HIV screening strategies was estimated.A decision tree model was established to analyze the cost-effectiveness differences of three different screening strategies under current domestic policies.Results The re-sidual risk of anti-HIV-1+2 ELISA,HIV Ag/Ab1+2 ELISA and ELISA+NAT were 1.17×10-6,0.84×10-6 and 0.59×10-6,re-spectively.According to decision tree model analysis,HIV Ag/Ab1+2 ELISA had a cost-effectiveness advantage over an-ti-HIV 1+2 ELISA when there was no NAT,but the advantage of HIV Ag/Ab1+2 ELISA disappeared when there was one NAT.The cost of HIV reagents,the cost of HIV treatment and the cost of false positive discarding were sensitive fac-tors of the model.Conclusion In this area,one anti-HIV 1+2 ELISA combined with one NAT has a cost-effectiveness advantage.Blood centers need to confirm and evaluate the ELISA reagents used before conducting HIV screening.Un-der the premise of ensuring sensitivity,reagent cost and reagent false positive rate are the key factors.
HIV screeningdecision tree modelcost-effectiveness analysis
万方数据
维普
